Clinical Trial Update: Low-Dose IL-2 For The Reduction Of Vascular Inflammation In ACS -Clinical Outcomes & Follow-up Study

View source ↗

Summary

A clinical trial evaluating low-dose interleukin-2 to reduce vascular inflammation in patients with acute coronary syndrome, currently recruiting at Cambridge U…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• Low-dose Interleukin-2 (interleukin-2)

Snippet

Sponsor: Cambridge University Hospitals NHS Foundation Trust | Conditions: Acute Coronary Syndromes | Status: RECRUITING